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HDL function as a predictor of coronary heart disease events: 
time to re-assess the HDL hypothesis?
The association of high HDL cholesterol concentrations 
with decreased risk of coronary heart disease was 
ﬁ rst reported more than 40 years ago, and has since 
been conﬁ rmed in numerous population studies. The 
strength of this association led to the hypothesis that 
interventions that increase plasma HDL cholesterol 
concentrations would reduce risk of coronary heart 
disease. Although interventions that increase HDL 
cholesterol concentrations reduce atherosclerosis 
in animals,1 trials of niacin2 and the cholesteryl ester 
transfer protein (CETP) inhibitor dalcetrapib3 have 
shown no beneﬁ t compared with placebo for clinical 
outcomes in human beings. Furthermore, treatment 
with the CETP inhibitor torcetrapib caused harm, 
possibly as a result of oﬀ -target eﬀ ects of the drug.4 
Genetics studies have suggested that polymorphisms 
that aﬀ ect HDL cholesterol concentration are 
associated with risk of coronary heart disease only 
when accompanied by a concomitant reduction in LDL 
cholesterol or triglyceride concentrations.5
These negative outcomes have shifted the focus 
of HDL research to strategies that improve the 
cardioprotective functions of HDLs, rather than 
increasing HDL cholesterol concentration as a means 
of reducing cardiovascular risk. HDLs have several 
cardioprotective functions. They inhibit inﬂ ammation 
in multiple cell types and prevent LDL oxidation.7 HDLs 
are also antithrombotic and anti-diabetic.6 The most 
studied function of HDLs and their main apolipoprotein, 
apoA-I, is as acceptors of the excess cholesterol that 
eﬄ  uxes from macrophages in the artery wall in the 
ﬁ rst step of the potentially anti-atherogenic reverse 
cholesterol transport pathway.
The ﬁ rst evidence of a relation between cholesterol 
eﬄ  ux capacity and risk of coronary heart disease 
came from a cross-sectional study7 of people with and 
without coronary heart disease. Serum samples from 
these participants were depleted of apoB-containing 
lipoproteins, leaving HDLs as the sole lipoproteins. When 
the capacity of these samples to eﬄ  ux radiolabelled 
cholesterol from mouse macrophages was assessed, 
cholesterol eﬄ  ux capacity correlated inversely with 
carotid intima media thickness and angiographically 
determined coronary artery disease. This relation was 
still apparent after adjusting for HDL cholesterol and 
apoA-I concentrations.
This result was conﬁ rmed in an outpatient cohort 
by other investigators.8 However, investigation of an 
angiography case-control cohort as part of the same 
study showed a paradoxical positive association of 
cholesterol eﬄ  ux capacity with the risk of a major 
cardiovascular event.8 These contradictory ﬁ ndings 
suggested that the relation of cholesterol eﬄ  ux 
capacity to cardiovascular events might be population-
speciﬁ c. They also indicate that interpretation of 
results that depict the cholesterol eﬄ  ux capacity of 
apoB-depleted serum is complex and could depend on 
multiple factors, including the relative concentrations 
of mature, spherical HDL and lipid-free apoA-I in 
the apoB-depleted serum, the nature of the donor 
macrophages, and the assay conditions. Despite 
these caveats, most studies support the idea that HDL 
function, at least in the context of cholesterol eﬄ  ux 
capacity, is inversely associated with risk of coronary 
heart disease.
The ﬁ rst evidence that serum cholesterol eﬄ  ux 
capacity predicts cardiovascular events was reported in 
2014,9 when the cholesterol eﬄ  ux capacity of baseline 
plasma samples from disease-free participants in 
the Dallas Heart Study was assessed and related to 
incident cardiovascular events. This study showed an 
inverse association of cholesterol eﬄ  ux capacity and 
HDL particle concentration, but not HDL cholesterol 
concentration, with incident cardiovascular events. 
However, this study was done with ﬂ uorescently 
labelled cholesterol in an assay that had not been 
rigorously validated. Furthermore, because there were 
few events in the Dallas Heart Study, it was important 
that the ﬁ ndings were conﬁ rmed in an independent 
cohort, using radiolabelled cholesterol to assess 
cholesterol eﬄ  ux capacity. 
Such a study is reported in The Lancet Diabetes & 
Endocrinology, in which radiolabelled cholesterol was 
used to measure the cholesterol eﬄ  ux capacity of 
apoB-depleted serum in a prospective investigation of 
1745 patients with incident coronary heart disease and 
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Chronic kidney disease is deﬁ ned as abnormalities of 
kidney structure or function, present for more than 
3 months, with implications for health.1 Criteria include 
either evidence of kidney damage (usually a urinary 
albumin-to-creatinine ratio [ACR] ≥30 mg/g) or a 
glomerular ﬁ ltration rate (GFR) less than 60 mL/min 
per 1·73 m². Indeed, chronic kidney disease is classiﬁ ed 
according to categories of persistent albuminuria 
(A1 through A3) and GFR (G1 through G5; ﬁ gure). 
A key notion is the requirement for implications for 
health. Thus, higher A and G categories are associated 
with increased risk of kidney disease progression, all-
cause death, and cardiovascular death.1 However, the 
contribution of albuminuria and GFR to cardiovascular 
risk prediction beyond traditional risk factors is 
controversial. This controversy is reﬂ ected in the 
heterogeneity of guidelines for primary prevention of 
cardiovascular disease in their use of risk stratiﬁ cation 
by albuminuria and GFR.2–4 The 2013 Kidney Disease: 
Improving Global Outcomes (KDIGO) guideline for 
lipids in chronic kidney disease recommends statins 
or statin plus ezetimibe for individuals aged 50 years 
or older with urinary ACR of 30 mg/g or higher or 
GFR less than 60 mL/min per 1·73 m², and suggests 
statins in patients with diabetes aged 18 years or 
older within these urinary ACR and GFR categories.2 
This recommendation expands the population to be 
prescribed statins by millions of additional patients 
compared with the 2013 guideline from the American 
College of Cardiology and American Heart Association, 
which does not incorporate GFR or urinary ACR for risk 
assessment.3 Both guidelines focus on prevention of 
atherosclerotic events. Indeed, heart failure and non-
coronary cardiac death were excluded from the primary 
outcome of a key statin trial in chronic kidney disease.5 
The 2012 European guidelines on cardiovascular disease 
prevention focused on overall cardiovascular risk.4 
Estimated GFR less than 60 mL/min per 1·73 m² was 
viewed to confer high or very high risk, whereas urinary 
ACR of 30–300 mg/g was only viewed to confer risk in 
1749 healthy controls from the EPIC-Norfolk study.10 
The results show a signiﬁ cant and inverse correlation of 
cholesterol eﬄ  ux capacity with incident coronary heart 
disease events, thus conﬁ rming the ﬁ ndings from the 
Dallas Heart Study. Additionally, the results from the 
EPIC-Norfolk substudy show that the relation between 
cholesterol eﬄ  ux capacity and incident coronary 
heart disease events was independent of multiple 
cardiovascular risk factors and remained signiﬁ cant 
after adjustment for HDL cholesterol and apoA-I 
concentrations.
This conclusion strengthens the case that at least one 
of the cardioprotective functions of HDLs is a predictor 
of cardiovascular events. It also raises the possibility that 
perhaps it is time to redeﬁ ne the HDL hypothesis. The 
results of ongoing outcome trials with CETP inhibitors 
should provide further insight into whether HDL 
function is key to cardioprotection.
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Humble kidneys predict mighty heart troubles
